In summary, both Cyclin D1 protein overexpression and YY1 genomic amplification seem to predict favorable outcome of NSCLC patients; these do not overlap with LOH for hDMP1 which is another favorable prognostic factor. This evidence concerns the gene DMTF1 and non-small cell lung carcinoma.